Shares of Biocept Inc (NASDAQ:BIOC) saw unusually-high trading volume on Thursday . Approximately 2,018,705 shares were traded during trading, an increase of 759% from the previous session’s volume of 234,948 shares.The stock last traded at $2.34 and had previously closed at $2.23.
BIOC has been the subject of several recent research reports. ValuEngine upgraded shares of Biocept from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Dawson James reiterated a “buy” rating on shares of Biocept in a research note on Wednesday, October 3rd. Finally, Zacks Investment Research upgraded shares of Biocept from a “sell” rating to a “hold” rating in a research note on Monday, August 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $0.92.
The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.08 and a current ratio of 1.20. The company has a market cap of $5.32 million, a price-to-earnings ratio of -0.10 and a beta of 1.63.
Biocept (NASDAQ:BIOC) last released its earnings results on Tuesday, August 14th. The medical research company reported ($2.70) earnings per share for the quarter, beating the consensus estimate of ($3.30) by $0.60. Biocept had a negative net margin of 642.49% and a negative return on equity of 587.80%. The firm had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.09 million. As a group, sell-side analysts expect that Biocept Inc will post -9.05 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Biocept stock. BlackRock Inc. lifted its position in shares of Biocept Inc (NASDAQ:BIOC) by 1.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 794,302 shares of the medical research company’s stock after acquiring an additional 14,403 shares during the period. BlackRock Inc. owned 34.99% of Biocept worth $159,000 as of its most recent filing with the SEC.
Biocept Company Profile (NASDAQ:BIOC)
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Featured Article: How to Invest in Growth Stocks
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.